GlassScriptPhysician profile
Stephen A Gephardt
NPI 1154307635
$13,873.20
in general payments reported to CMS, 2019-2025
54 companies · $878 in 2025
The $878 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,742 · 2020: $1,490 · 2021: $2,215 · 2022: $3,204 · 2023: $2,090 · 2024: $1,255 · 2025: $878.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,223.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $2,135.98 | 2019-2024 | Senza |
| Abbvie INC. | $1,537.33 | 2021-2025 | |
| Abbott Laboratories | $1,265.94 | 2019-2025 | Proclaim |
| Scilex Pharmaceuticals INC. | $924.81 | 2019-2025 | Ztlido |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $813.61 | 2019-2025 | Relistor |
| Boston Scientific Corporation | $600.41 | 2019-2025 | Intracept, Coveredge 32, Clik X |
| Daiichi Sankyo INC. | $594.26 | 2019 | |
| Forte Bio-Pharma LLC | $499.67 | 2019-2025 | Prolate, Nalocet, Tanlor |
| Allergan, INC. | $468.19 | 2019-2022 | |
| Medtronic, INC. | $461.31 | 2022-2024 | Intellis Adaptivestim |
| Pfizer INC. | $361.06 | 2019-2025 | |
| Zyla Life Sciences, INC. | $337.05 | 2019-2020 | |
| Amgen INC. | $322.38 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $296.74 | 2019-2025 | Xtampza, Belbuca |
| Lundbeck LLC | $264.37 | 2020-2025 | Vyepti |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Gephardt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.